Khavinson's 'bronchial' tripeptide EDG; no airway study exists, and only one first-hand report was found.
Safety tier
Caution
strict bar
Positive
43%
of 1 report
Per month
≈ €72–100
estimate
Rank
#20
of 61 research peptides
At a glance
Onset
Not felt acutely; the one first-hand user judged it over weeks of a course.
Lasts
Taken as 1-month capsule courses repeated every 3-6 months, or 3-4 week injection cycles; the one report says the benefit faded within a couple of months.
Access
Grey market
Best effects
Claimed: easier breathing and fewer flare-ups in asthma or chronic bronchitis (one mixed first-hand report, one second-hand) · claimed: lung recovery after smoking or pneumonia (manufacturer)
Downsides
Benefit, if any, may not outlast the course · grey-market vials are dosed 50-100x higher than the capsules with no rationale · no effect can be separated from inhalers and other peptides used alongside
Typical use
Capsules: 1-2 capsules (0.1-0.2 mg) twice a day with meals for 1 month, repeated after 3-6 months (manufacturer). Grey-market vials: vendor guides suggest 10-20 mg subq every other day for 20-30 days, a dose with no published basis.
Stacked with
Stacked with
Bronchogen: The usual pairing for asthma, COPD or ex-smokers' lungs; the one first-hand report ran both. · BPC-157 or TB-500: Suggested by vendor guides for 'lung repair' protocols; no reports of the combination.
Safety
Watch
In the only cell study, Chonluten alone doubled apoptosis and triggered mild TNF release in undifferentiated human monocytes; a single-group in-vitro signal of unknown meaning · Grey-market injectable vials: purity, sterility and identity unverified
Tier by safety barStrict CautionBalanced CautionEvidence only Clean
Seen harm0 of 3
Mechanism1 of 3
Data gap3 of 3
Silent harm1 of 3
Product3 of 3
Never if
Pregnancy or breastfeeding (no human reproductive data) · Asthma or COPD patients replacing prescribed inhalers or steroids with it
Why each score
Seen harm 0/3
No serious adverse event has been reported in any source or first-hand account, but the zero reflects almost no documented human exposure (one first-hand Reddit report, an unpublished patent example), not reassurance. Peptx: Chonluten, claims versus the published evidence ↗
Mechanism 1/3
No named pathway to serious harm. The only signal is single-group in-vitro work in which Chonluten alone caused mild TNF release and about twice the apoptosis of other peptides in undifferentiated human monocytes, alongside anti-inflammatory effects in macrophages. Avolio et al. 2022: Khavinson peptides in THP-1 monocytes/macrophages ↗
With no credible mechanism, rated on the most plausible harms: injection-site or allergic reactions to grey-market vials and stomach upset from capsules, which are mostly noticed at once and stop with the course.
Product 3/3
Reddit users mostly buy grey-market 20-30 mg vials of EDG powder for subcutaneous injection, of unverified purity and sterility; the Khavinson-line capsules (0.1 mg per capsule, sold as a supplement) are the lower-risk alternative. PepGrades: Chonluten 20 mg vial prices across vendors ↗
Far too few reports to judge. The only first-hand account found is an asthmatic who ran Chonluten with Bronchogen: it seemed to help at the time, then the asthma came back 'with a vengeance' a couple of months later. A widely upvoted story of a builder's brick-dust asthma clearing after eight weeks of injected Chonluten is second-hand (a friend), so it is not counted. The rest of Reddit is smokers, COPD and asthma patients asking for a protocol, plus a vendor-affiliate guide pushing 10-20 mg injections. Felt nothing: Too few reports to count (one first-hand report).
They did seem to help at the time but for the past couple of months it came back with a vengeance
Mixedone course
asthma; ran Chonluten together with Bronchogen
Studies
Evidence
Animal only — One rat gastric-ulcer study (as T-34), one cell-line study in monocytes, docking models and an unpublished patent example in 80 healthy men under simulated altitude. Nothing has been published in airway cells, lung tissue or respiratory patients; the group's own bronchial-epithelium work used a different peptide, Bronchogen (AEDL).
Caveat
Evidence that Chonluten does anything in the lungs is effectively absent: the respiratory label comes from the developers' tissue mapping and a review that cites a stomach study. EDG is a tiny acidic tripeptide with no named harm pathway, so the verdict reflects thin data rather than a credible risk, but nobody has published human safety data either, and injected grey-market vials (at 100x the capsule dose) are a different exposure from the capsules.
The peptide's chain of amino acids from its start (the N-terminus) to its end, one bead and one letter for each: A alanine, C cysteine, D aspartic acid, E glutamic acid, F phenylalanine, G glycine, H histidine, I isoleucine, K lysine, L leucine, M methionine, N asparagine, P proline, Q glutamine, R arginine, S serine, T threonine, V valine, W tryptophan, Y tyrosine. A modification such as an N-acetyl cap or a C-terminal amide changes how long it lasts in the body. Length tells related peptides apart, from a two-residue dipeptide like carnosine to a 43-residue protein like thymosin beta-4, and predicts neither effect nor safety.
Report grades
Every first-hand Reddit or X report is graded on its own, from glowing through positive, mixed, nothing and negative to bad reaction, and the bar shows how those grades split. Posts that look vendor-adjacent stay on the peptide's page but are left out of the counts.
GlowingPositiveMixedNothingNegativeBad reaction
% positive
The share of a peptide's graded Reddit and X reports that are glowing or positive, vendor-adjacent posts left out. A peptide with few reports is pulled toward the average of all reports, as if it had eight average ones besides its own, so two glowing posts cannot top the list. Peptides rank by this figure, those with no graded report yet after those with one, and Avoid ones after every other entry.
Researcher estimate
No first-hand report of this peptide has been graded yet, so the figure is the researchers' own rating out of 10 from what they read about it. It ranks after every peptide with graded reports until its own arrive.
Safety tier
Each peptide is tiered Clean, Caution or Avoid from its five risk axes under the chosen safety bar. An Avoid peptide carries a real risk of harm, a plausible route to serious harm rather than mere unpleasantness, so it stays listed with the reason but ranks behind every other entry, however good its reviews.
Safety bar
The safety bar sets how much risk it takes to rate a peptide Avoid. Strict: out on any serious mechanism with little human data, or any documented serious harm. Balanced: out on documented serious harm (unless it is obvious, reversible and from a regulated product), or a serious mechanism whose harm would be silent with no human data at all. Evidence only: out only on documented serious harm in humans that is lasting, delayed or from grey-market product.
Seen harm
Documented serious adverse events in humans, from 0 for none despite real exposure to 3 for deaths or several well-documented serious harms. Serious means a hospital or emergency visit or harm lasting weeks, so a headache or a bad night does not count.
Mechanism
A plausible biological route to serious harm at the doses people use, such as growth-factor signalling, hormone-axis suppression, heart or blood-pressure effects or immune activation. It runs from 0 when none is known to 3 when a dangerous pathway has been shown in living animals.
Data gap
How little human safety data exists for the molecule actually sold, from 0 for an approved drug with large trials and years of use to 3 for no human safety data at all. A modified analogue does not inherit its parent's trials.
Silent harm
Whether the feared harm would show quickly or stay hidden, from 0 when it is obvious and goes on stopping to 3 when it is silent and delayed, like tumour promotion or slow organ damage. User reports cannot reveal a harm that takes years to appear, so a high score here limits what good reviews can tell you.
Product
The risk of what people actually buy, from 0 for a regulated pharmacy or supplement product taken by mouth or on the skin to 3 for a grey-market injectable. In one dataset of 6,441 grey-market samples, 42–71% failed basic quality criteria and 15% carried endotoxin; taken by mouth or in the nose, a pack avoids the injection risks.
Evidence
The strongest kind of study behind the peptide's effects, from an approved drug through human controlled trials and small human studies to animal work or nothing of its own. Animal results often fail to carry over to people.
Access
How people get it: as an approved drug, a compounded prescription, an over-the-counter supplement or from the grey market, where nobody checks the vial. The channel decides both the legal position and the risk of a bad batch.
Price per month
Thirty days of the typical dose, from its low end to its high end, priced at the listing a careful buyer would choose: in stock, from a shop scoring 4 of 5 on trust (third-party tested where no score is set), failing that 3, a pure pack before a blend, a European shop first, then the cheapest per mg. The range is the dose's, not the shops'. A per-dose amount counts once a day unless the dose says otherwise. Prices are in euros at ECB rates of 2026-10-29, before shipping; the shop table keeps each listing's price per mg, per gram for bulk supplements. Where no listing can be priced the researchers' own estimate stands in, and says so.
Dose users report
The middle half of the daily doses stated in at least five first-hand reports, vendor posts left out. Where its middle sits more than twice above or below the declared dose, the month is priced at it as well, since what people take is what they pay for.
Shop trust
Each shop's trust on a 1–5 scale, read from its testing and its reputation: 1 for serious red flags (fabricated COAs, scam reports, impersonation, a closed shop), 2 for no public testing, a new shop or active complaints such as seized parcels, 3 for its own COAs or a short track record, 4 for verified third-party testing or a strong reputation, and 5 for third-party batch reports that name the shop, with years of good independent reputation. A shop without a score counts third-party batch testing as 4, its own COAs as 3 and no public tests as 2.
Best value
Within a category or a goal, a peptide that no other beats on both counts: none is rated more positively for the same or a lower monthly price, and none costs less for the same or a higher rating. The chart joins these into the best-value line; the cheapest of them and the best-rated of them both make it, so the line spans the trade-off from cheap to best. Avoid entries never count, and a peptide needs both a % positive and a price to be compared.
Testing
Whether the shop publishes lab results: third-party tested means an independent lab checks each batch, own COA means the shop's own certificate of analysis, and no public tests means neither. A certificate shows purity, not safety.
Added peptide
Some packs sold under one peptide's name hold a second one, such as 5 mg GHK-Cu in a nasal kit, stated only in the description. Sprayed in the nose or injected it reaches the blood like an injection, so it carries the risk of that route and is tiered as the injectable form, whatever its tier on the skin. A pack whose page gives no contents list may hold more than its name.